Platelet Aggregation InhibitorsAspirinTiclopidinePlatelet AggregationThrombosisThienopyridinesPlatelet Function TestsHemorrhageAnticoagulantsPurinergic P2Y Receptor AntagonistsDipyridamoleBleeding TimeThiophenesBlood PlateletsReceptors, Purinergic P2Y12Drug Therapy, CombinationFibrinolytic AgentsPlatelet ActivationPlatelet Glycoprotein GPIIb-IIIa ComplexAcute Coronary SyndromeDilazepStrokeWarfarinPhosphodiesterase 3 InhibitorsCoronary ThrombosisThromboembolismTreatment OutcomeSecondary PreventionPurinergic P2 Receptor AntagonistsStentsPostoperative HemorrhageRisk FactorsTetrazolesAngioplasty, Balloon, CoronaryPiperazinesPerioperative CareImmunoglobulin Fab FragmentsCardiovascular AgentsAdenosine DiphosphateIntracranial HemorrhagesMyocardial InfarctionRecurrenceIschemic Attack, TransientCerebrovascular DisordersAdministration, OralPlatelet AdhesivenessVitamin KCerebral HemorrhagePhenprocoumonRisk AssessmentCoronary Artery DiseaseBrain IschemiaPeripheral Vascular DiseasesProspective StudiesFollow-Up StudiesTime FactorsAdenosineHeparinReceptor, PAR-1PyridinesDrug ResistanceRetrospective StudiesThrombolytic TherapyRandomized Controlled Trials as TopicCardiovascular DiseasesAtrial FibrillationClinical Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsPractice Guidelines as TopicDose-Response Relationship, DrugAngiotensin-Converting Enzyme InhibitorsThrombinRegistriesDouble-Blind MethodCoronary DiseaseAdrenergic beta-AntagonistsIncidenceDrug-Eluting StentsMyocardial IschemiaCollagenPostoperative ComplicationsThromboxane B2Platelet CountAntibodies, MonoclonalThrombocytopeniaSulfinpyrazonePurpura, ThrombocytopenicPercutaneous Coronary InterventionPhenazopyridineThromboxanesAcenocoumarolIntracranial ThrombosisEmbolismHematomaPlatelet Membrane GlycoproteinsGraft Occlusion, VascularAryl Hydrocarbon HydroxylasesPurpura, Thrombocytopenic, IdiopathicEmbolism, CholesterolThrombelastography